# T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

> **NCT02772198** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 300 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, B-precursor
- Non-Hodgkin Lymphoma, B-cell

## Interventions

- **BIOLOGICAL:** CD19 CAR T cells

## Key facts

- **NCT ID:** NCT02772198
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2022-07
- **Final completion:** 2022-11
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772198, "T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02772198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*